Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pasteur effect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Pasteur effect. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-002366-18 Sponsor Protocol Number: GID17 Start Date*: 2008-06-30
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in the Elderly.
    Medical condition: Vaccination of elderly subjects aged 60 years and over with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002401-23 Sponsor Protocol Number: GID15 Start Date*: 2005-10-06
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with Intramuscular Vaccination with Vaxigrip® in Adults.
    Medical condition: Annual vaccination of healthy adult (18-60 years) for 3 consecutive years.
    Disease: Version SOC Term Classification Code Term Level
    10036897
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004573-32 Sponsor Protocol Number: 21-05 Start Date*: 2021-10-05
    Sponsor Name:Centre Hospitalier Annecy Genevois
    Full Title: Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) versus Standard-Dose (QIV-SD), in subjects 65 years of age and older on innate immunity, including gene expression.
    Medical condition: Healthy volunteers (influenza vaccination)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003078-28 Sponsor Protocol Number: IIV-273 Start Date*: 2013-08-22
    Sponsor Name:RIVM
    Full Title: Immunological effect of early extra MMR immunization in infants between 6 and 12 months of age in an outbreak setting
    Medical condition: healthy volunteer (immunological response to early extra measles immunization)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003466-39 Sponsor Protocol Number: Protocol_MAMA_studie_22/05/2018 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Antwerp
    Full Title: Pertussis immunization during pregnancy: assessment of the role of maternal antibodies on immune responses in term and preterm infants (the MAMA study)
    Medical condition: The effect of pertussis vaccination during pregnancy on the immune response after infant and childhood vaccinations in term and preterm infants.
    Disease:
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002452-40 Sponsor Protocol Number: Td500056 Start Date*: 2023-03-08
    Sponsor Name:Sanofi Pasteur
    Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg...
    Medical condition: Bacterial infections
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    21.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002282-30 Sponsor Protocol Number: 2014-2 Start Date*: 2014-07-30
    Sponsor Name:County council of Ostergotland
    Full Title: Effects of oxygen treatment on mechanisms involved in ischemia-reperfusion injury: A pilot study in healthy volunteers.
    Medical condition: Study performed in healthy male vonlunteers.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003616-49 Sponsor Protocol Number: SEACAP Start Date*: 2018-11-08
    Sponsor Name:Finnish Melanoma Group
    Full Title: The effect of seasonal prophylactic influenza vaccination and factors influencing the patients' immune-competence during anti-PD-1 treatment of patients with melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000775-32 Sponsor Protocol Number: H-030-014 Start Date*: 2013-08-13
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection
    Medical condition: Prevention of primary Clostridium difficile infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    20.0 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    20.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    20.0 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed) DK (Completed) PL (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-001113-33 Sponsor Protocol Number: AGO/REU/04/01 Start Date*: 2004-10-13
    Sponsor Name:University Hospital Ghent
    Full Title: Effect of TNFalpha blockade on the induction of specific B cell responses in vivo, using human spondyloarthropathy as model.
    Medical condition: Spondyloarthropathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008278-29 Sponsor Protocol Number: ABR16858METC08-342 Start Date*: 2009-07-20
    Sponsor Name:University Medical Center Utrecht
    Full Title: Is early revaccination after ALL therapy feasible ? Evaluation of loss of antibodies and responsiveness to (re)vaccination in children after treatment for acute lymphocytic leukemia
    Medical condition: To determine the effect of early (re) vaccination after acute lymphoblastic leukemia treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000850 Acute lymphoid leukemia in remission LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011523-31 Sponsor Protocol Number: 09/H0720/64 Start Date*: 2009-06-23
    Sponsor Name:R & D, Cambridge University Hospitals
    Full Title: A study of the immune response to vaccination in MS patients treated with alemtuzumab
    Medical condition: The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    9.1 10063400 Secondary progressive multiple sclerosis PT
    9.1 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001245-13 Sponsor Protocol Number: 4LB-LEO-P Start Date*: 2022-03-03
    Sponsor Name:4Living Biotech SAS
    Full Title: A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO)
    Medical condition: Severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001104-36 Sponsor Protocol Number: IIV-291 Start Date*: 2016-06-01
    Sponsor Name:RIVM
    Full Title: Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands
    Medical condition: immunological response to an extra mumps immunization (in healthy volunteers)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004774-85 Sponsor Protocol Number: IDEC 102-12 Start Date*: 2005-04-13
    Sponsor Name:Biogen Idec Inc
    Full Title: A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens
    Medical condition: Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001042-18 Sponsor Protocol Number: A3L40 Start Date*: 2014-08-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: This Phase III multi-center study of DTaP-IPV-Hib, with or without Hep B, used as a booster vaccine in healthy infants and toddlers will be conducted with two controlled, blind-observer trial arms ...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    17.0 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    17.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    17.0 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001496-11 Sponsor Protocol Number: 08020 Start Date*: 2010-01-15
    Sponsor Name:University of Nottingham
    Full Title: The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple Sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001299-79 Sponsor Protocol Number: IMVX2014 Start Date*: 2014-10-06
    Sponsor Name:Department of Infectious Diseases, Odense University Hospital
    Full Title: Pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy
    Medical condition: Immunoresponse on pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10069594 Pneumococcal immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004123-23 Sponsor Protocol Number: Immunovax_Renal Start Date*: 2017-04-20
    Sponsor Name:Department of Infectious Diseases, Odense University Hospital
    Full Title: Immunization of immunosuppressed patients – Knowledge, practices and serological response
    Medical condition: Immunoresponse on pneumococcal vaccination of kidney transplant recipients in immunomodulatory therapy or patients with end stage renal disease.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    21.1 100000004865 10069594 Pneumococcal immunization LLT
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001731-31 Sponsor Protocol Number: YFV_001 Start Date*: 2019-09-02
    Sponsor Name:Aarhus University Hospital
    Full Title: Cytotoxicity of Yellow Fever specific CD8 T cells Following YF-17D Vaccination
    Medical condition: Healthy individuals or HIV-1 infected individuals
    Disease: Version SOC Term Classification Code Term Level
    22.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 11:29:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA